Finanzas de Kiniksa Pharmaceuticals Ltd (KNSA)KNSAKiniksa Pharmaceuticals Ltd

Evaluating the bottom line, Kiniksa Pharmaceuticals International, PLC maintains a gross margin of 53.29%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.97%, while the net margin is 16.56%. These profitability ratios, combined with a Return on Equity (ROE) of 17.59%, provide a clear picture of how effectively KNSA converts its operational activities into shareholder value.

In the context of the broader market, KNSA competes directly with industry leaders such as BLTE and GRFS. With a market capitalization of $7.48B, it holds a leading position in the sector. When comparing efficiency, KNSA's gross margin of 53.29% stands against BLTE's N/A and GRFS's 37.57%. Such benchmarking helps identify whether Kiniksa Pharmaceuticals International, PLC is trading at a premium or discount relative to its financial performance.

Kiniksa has shown impressive financial performance, with Q2 2026 net product revenue of $243.6 million, up 55% year-over-year. The gross margin is strong at 90.32%, and net income has improved significantly, reaching $25.4 million in Q2 2026.